152 related articles for article (PubMed ID: 26932854)
1. [Clinical and biological characteristics multiple myeloma with 1q21 amplification].
Zhong S; Li C; Yi S; Qiu L
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(8):615-9. PubMed ID: 26932854
[TBL] [Abstract][Full Text] [Related]
2. [Investigation of chromosome 1 aberrations in patients with multiple myeloma using cIg-FISH method and its significance].
Yang RF; Li CM; Qiu HR; Lu H; Wu HX; Xu JR; Li JY; Chen LJ
Zhonghua Xue Ye Xue Za Zhi; 2010 Dec; 31(12):804-8. PubMed ID: 21223735
[TBL] [Abstract][Full Text] [Related]
3. [Investigation of 1q21 amplification in patients with multiple myeloma using I-FISH and cIg-FISH].
Yang RF; Li CM; Qiu HR; Lu H; Wu HX; Xu JR; Zhang P; Li JY; Chen LJ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):686-9. PubMed ID: 22161106
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
An G; Xu Y; Shi L; Shizhen Z; Deng S; Xie Z; Sui W; Zhan F; Qiu L
Haematologica; 2014 Feb; 99(2):353-9. PubMed ID: 24213147
[TBL] [Abstract][Full Text] [Related]
5. The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
Gao L; Liu Y; Li Y; Feng L; Wang Z; Wen L; Wang F; Huang X; Lu J; Lai Y
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):535-544. PubMed ID: 35292207
[TBL] [Abstract][Full Text] [Related]
6. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
7. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
[TBL] [Abstract][Full Text] [Related]
8. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
9. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of 1q21 amplification in multiple myeloma].
Abramova TV; Obukhova TN; Mendeleeva LP; Pokrovskaya OS; Gribanova EO; Ryzhko VV; Grebenyuk LA; Nareyko MV; Solovyev MV; Votyakova OM; Kulikov SM; Rusinov MA; Savchenko VG
Ter Arkh; 2017; 89(7):32-38. PubMed ID: 28766538
[TBL] [Abstract][Full Text] [Related]
11. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
Hanamura I; Stewart JP; Huang Y; Zhan F; Santra M; Sawyer JR; Hollmig K; Zangarri M; Pineda-Roman M; van Rhee F; Cavallo F; Burington B; Crowley J; Tricot G; Barlogie B; Shaughnessy JD
Blood; 2006 Sep; 108(5):1724-32. PubMed ID: 16705089
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
Deng P; Zhou YL; Wei YL; Li P; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
[TBL] [Abstract][Full Text] [Related]
13. [Application Value of CD138 MACS-FISH in the Genetic Diagnosis of Plasma Cell Dyscrasia].
Mei JG; Li HQ; Cao HQ; Shao JJ; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1437-1442. PubMed ID: 27784371
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
Kastritis E; Migkou M; Dalampira D; Gavriatopoulou M; Fotiou D; Roussou M; Kanellias N; Ntanasis-Stathopoulos I; Malandrakis P; Theodorakakou F; Sevastoudi A; Eleutherakis-Papaiakovou E; Triantafyllou T; Terpos E; Katodritou E; Dimopoulos MA
Am J Hematol; 2022 Sep; 97(9):1142-1149. PubMed ID: 35731917
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
[TBL] [Abstract][Full Text] [Related]
16. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.
Stella F; Pedrazzini E; Baialardo E; Fantl DB; Schutz N; Slavutsky I
Blood Cells Mol Dis; 2014 Sep; 53(3):110-7. PubMed ID: 24973170
[TBL] [Abstract][Full Text] [Related]
18. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population.
Yu W; Guo R; Qu X; Qiu H; Li J; Zhang R; Chen L
Onco Targets Ther; 2016; 9():295-302. PubMed ID: 26834489
[TBL] [Abstract][Full Text] [Related]
19. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M
Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609
[TBL] [Abstract][Full Text] [Related]
20. Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.
Sawyer JR; Tian E; Heuck CJ; Johann DJ; Epstein J; Swanson CM; Lukacs JL; Binz RL; Johnson M; Sammartino G; Zangari M; Davies FE; van Rhee F; Morgan GJ; Barlogie B
Blood; 2015 Jun; 125(24):3756-9. PubMed ID: 25943786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
